Line probe assay for monitoring drug resistance in Hepatitis B virus- infected patients during antiviral therapy

Journal of Clinical Microbiology

Volumn 38, Issue 2, 2000, Pages 702-707

  Stuyver, Lieven ^a,d   Van Geyt, Caroline ^a   De Gendt, Sija ^a   Van Reybroeck, Georges ^a   Zoulim, Fabien ^b   Leroux Roels, Geert ^c   Rossau, Rudi ^a  

^a INNOGENETICS   (Belgium)

^b INSERM   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; FAMCICLOVIR; LAMIVUDINE;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; VIRUS STRAIN;

HEPATITIS B VIRUS; RNA VIRUSES;

EID: 0033971684     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.2.702-707.2000     Document Type: Article

References (27)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. J. Tyrell, N. Brown, The Lamivudine Clinical Investigation Group, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Bartholmensz, A., R. F. Schinazi, and S. A. Locarnini. 1998. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hep. Rev. 4:167-187.
3. Buti, M., R. Jardi, M. Cotrina, F. Rodriguez-Frias, R. Esteban, and J. Guardia. 1998. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J. Hepatol. 28:510-513.
4. Chayama, K., Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
5. Gunther, S., G. Sommer, U. Plikat, A. Iwanska, S. Wain-Hobson, H. Will, and A. Meyerhans. 1997. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 18:104-108.
6. Günther, S., F. van Breunig, S. Santantonio, M.-C. Jung, G. B. Gaeta, L. Fisher, M. Sterneck, and H. Will. 1999. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J. Hepatol. 30:749-754.
7. Heijtink, R. A., J. Kruining, P. Honkoop, M. C. Kuhns, W. C. Hop, A. D. Osterhaus, and S. W. Schalm. 1997. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J. Med. Virol. 53:282-287.
8. Honkoop, P., H. G. M. Niesters, R. A. M. de Man, A. D. M. E. Osterhaus, and S. W. Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. J. Hepatol. 26:1393-1395.
9. Ladner, S. K., T. J. Miller, and R. W. King. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42:2128-2131.
10. Lai, C. L., R. N. Chien, N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K.-Y. Ng., P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. One year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
11. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
12. Main, J., J. L. Brown, C. Howells, R. Galassini, M. Crossay, P. Karayiannis, P. Georgiou, G. Atkinson, and H. C. Thomas. 1996. A double blind, placebo controlled study to assess the effect of famcicluvir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hep. 3:211-215.
13. Melagari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
14. Mutimer, D., N. Naoumov, P. Honkoop, G. Marinos, M. Ahmed, R. de Man, P. McPhillips, M. Johnson, R. Williams, E. Elias, and S. Schalm. 1998. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol. 28:923-929.
15. Niesters, H. G. M., P. Honkoop, E. B. Haagsma, R. A. de Man, S. W. Schalm, and A. D. M. E. Osterhaus. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177:1382-1385.
16. Pichoud, C., B. Seignères, Z. Wang, C. Trèpo, and F. Zoulim. 1998. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29: 230-237.
17. Pillay, D., A. Bartholomeusz, P. Cane, D. Mutimer, R. F. Schinazi, and S. Locarnini. 1998. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int. Antivir. News 6:167-169.
18. Poch, O., I. Sauvaget, M. Delarue, and N. Tordo. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:3867-3874.
19. Prange, R., and R. E. Streeck. 1995. Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J. 14:247-256.
20. Severini, A., X. Y. Liu, J. S. Wilson, and D. L. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
21. Stuyver, L., A. Wyseur, W. van Arnhem, F. Hernandez, and G. Maertens. 1996. A second-generation line probe assay for hepatitis C virus. J. Clin. Microbiol. 34:2259-2266.
22. Stuyver, L., A. Wyseur, A. Rombaut, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. F. Schinazi, and R. Rossau. 1997. Line probe assay for the rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
23. Stuyver, L., S. De Gendt, C. Van Geyt, F. Zoulim, M. Fried, R. F. Schinazi, and R. Rossau. Characterization of a new hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol., in press.
24. Tillmann, H. L., C. Trautwein, T. Bock, K. H. W. Böker, E. Jäckel, M. Glowienka, K. Oldhafer, I. Bruns, J. Gauthier, L. D. Condreay, H.-R. Raab, and M. P. Manns. 1999. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244-256.
25. Tipples, G. A., M. M. Ma, K. P. Fisher, V. G. Bain, N. M. Kneteman, and D. L. J. Tyrell. 1996. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
26. Van Geyt, C., S. De Gendt, A. Rombaut, A. Wyseur, G. Maertens, R. Rossau, and L. Stuyver. 1998. A line probe assay for hepatitis B virus genotypes, p. 139-145. In R. F. Schinazi, J. P. Sommadossi, and H. Thomas (ed.), Therapies of viral hepatitis. International Medical Press, London, United Kingdom.
27. Zoulim, F., and C. Trépo. 1998. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:151-168.